Towards Better Pharmaceutical Provision in Europe—Who Decides the Future?

Horgan, Denis; Španić, Tanja; Apostolidis, Kathi; Curigliano, Giuseppe; Chorostowska‐Wynimko, Joanna; Dauben, Hans-Peter; Lal, Jonathan A.; Dziadziuszko, Rafał; Mayer‐Nicolai, Christine; Kozaric, Marta; Gutiérrez-Ibarluzea, Iñaki; Fandel, Marie-Helene; Lopert, Ruth

doi:10.3390/healthcare10081594

Cited by 3 publications

(4 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During the pandemic, therapeutic drugs targeting COVID-19 were in a state of de ciency for a long time. Therefore, capacity building in drug R&D was more important [13], especially accelerating the improvement of R&D capacity in China and adopting a series of incentive tools to ensure that R&D products were marketed faster, while improving the motivation of R&D subjects. In this process, the division of labor between national and provincial policymakers in China was clear, and national authorities tended to adopt more direct capacity-building tools to enhance the overall drug R&D capacity, while all provincial regions paid more attention to adding fast tracks to the process of drug R&D review and approval, adopting nancial incentives to accelerate the speed of R&D review and approval, and enhance R&D motivation of relevant organizations.…”

Section: Multidimensional Integrated Analysis Of Policy Tools and The...mentioning

confidence: 99%

The practice of drug emergency supply in China from a policy mix perspective

Jie-ying,

Jun,

Xue-ya

et al. 2024

Preprint

View full text Add to dashboard Cite

Background This study aims to analyze relevant policy texts, explore and determine the focal points and inadequacies of the Chinese government in guaranteeing supplies of medicines, and provide advice on how to make better policies about drug supply when public health emergencies occur. Methods We selected 559 documents that guided the support of drug supply during emergencies issued by governments at both the national and provincial levels from December 1, 2019, to February 28, 2023. In addition, we developed a four-dimensional analysis framework of the issuing agency, issuing period, policy tools, and drug supply chain to analyze specific policy items, determine their basic characteristics, and quantitatively analyze them from a policy mix perspective. Results The analysis using policy tools showed that the national government tended to call on stakeholders in all aspects of drug supply to fulfil their responsibilities, and both national and provincial governments tended to use incentive tools, such as opening up urgent drug supply tracks and applying financial incentives to promote drug supply. However, managing stakeholders’ behaviors in drug supply and the capacity building to guarantee drug supply are still lacking and require improvement. From the perspective of the drug supply chain, the national government has paid much attention to the distribution of drugs, whereas attention to the supply of drug substances has been lacking. As various stages of the COVID-19 pandemic, the number of policies related to drug supply increased slowly after a surge at the beginning of the pandemic and then rapidly decreased. From the policy mix perspective, the analysis showed that incentives were lacking in drug research and development, and capacity building was not discussed much in the drug manufacturing process. Conclusions We suggest enhancing the complementarity and cohesion of the policy content issued by national and provincial governments, strengthening the coordination and connection between policymaking bodies, optimizing the internal structure of policy tools, improving the performance of various policy strategies, and using appropriate policy tools to create policies suited to various stages of emergencies and drug supply chains.

show abstract

Section: Multidimensional Integrated Analysis Of Policy Tools and The...mentioning

confidence: 99%

The practice of drug emergency supply in China from a policy mix perspective

Jie-ying,

Jun,

Xue-ya

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…In addition, a scaled medical institution should also invest its resources into medical research and development to improve medical quality. 13…”

Section: Introductionmentioning

confidence: 99%

“…In addition, a scaled medical institution should also invest its resources into medical research and development to improve medical quality. 13 Researchers have been studying the factors contributing to the success of PPP in two primary angles: the theoretical and the practical. From the theoretical angle, value creation is considered the core of PPP management, and studies were conducted to focus on how public-private collaborations coordinate to generate social value.…”

Section: Introductionmentioning

confidence: 99%

Analyzing Financial Efficiency of Public-Private Partnerships Hospitals in Taiwan

Gao,

Chou,

Chang

et al. 2023

Asia Pac J Public Health

View full text Add to dashboard Cite

This study evaluates the management capacity ability and profitable capacity of eight public-private partnership hospitals in Taiwan from 2015 to 2020. By conducting various ratio analyses of the financial statement, this study found these hospitals have achieved a balance between management efficiency and profitability, thereby confirming the viability of the PPP model for hospital management. In addition, the subject hospitals play a vital role as isolation hospitals during the COVID-19 pandemic. Beyond offering medical assistance to infected individuals, these hospitals contribute to the integrity of Taiwan’s medical network, mitigating the impact of the pandemic. Overall, establishing and managing hospitals with PPP partnership is a feasible solution as it alleviates governmental financial burdens related to medical welfare and achieves profitability.

show abstract

“…For life-threatening or debilitating diseases that have limited or no treatment options, access to new drugs can provide relief and improve the quantity and quality of life for existing patients with ominous prognosis. However, many healthcare stakeholders claim that numerous patients with life-threatening or debilitating diseases still do not have access to new and innovative medicines ( Baird, et al, 2014 ; Panteli and Edwards, 2018 ; Horgan, et al, 2022 ).…”

Section: Introductionmentioning

confidence: 99%

The challenges of access to innovative medicines with limited evidence in the European Union

Vallano,

Pontes,

Agustí

2023

Front. Pharmacol.

View full text Add to dashboard Cite

The European Medicines Agency (EMA) fosters access to innovative medicines through accelerated procedures and flexibility in the authorization requirements for diseases with unmet medical needs, such as many rare diseases as well as oncological diseases. However, the resulting increase of medicines being marketed with conditional authorizations and in exceptional circumstances has lead to higher clinical uncertainty about their efficacy and safety than when the standard authorizations are applied. This uncertainty has significant implications for clinical practice and the negotiation of pricing and reimbursement, particularly as high prices are based on assumptions of high value, supported by regulatory prioritization. The burden of clinical development is often shifted towards public healthcare systems, resulting in increased spending budgets and opportunity costs. Effective management of uncertainty, through appropriate testing and evaluation, and fair reflection of costs and risks in prices, is crucial. However, it is important not to sacrifice essential elements of evidence-based healthcare for the sake of access to new treatments. Balancing sensitive and rational access to new treatments, ensuring their safety, efficacy, and affordability to healthcare systems requires thoughtful decision-making. Ultimately, a responsible approach to timely access to innovative medicines that balances the needs of patients with healthcare systems’ concerns is necessary. This approach emphasizes the importance of evidence-based decision-making and fair pricing and reimbursement.

show abstract

Towards Better Pharmaceutical Provision in Europe—Who Decides the Future?

Cited by 3 publications

References 59 publications

The practice of drug emergency supply in China from a policy mix perspective

The practice of drug emergency supply in China from a policy mix perspective

Analyzing Financial Efficiency of Public-Private Partnerships Hospitals in Taiwan

The challenges of access to innovative medicines with limited evidence in the European Union

Contact Info

Product

Resources

About